Results 81 to 90 of about 6,510 (202)

Potential drug interaction after withdrawal of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 infection

Journal of Global Antimicrobial Resistance
Background: Nirmatrelvir-ritonavir is effective in the treatment of SARS-CoV-2 infection. It can cause drug‒drug interactions (DDIs), even several days after withdrawal, due to irreversible inhibition of the cytochrome enzyme.
Yun Han, Yonglan Gou, Jieqiong Liu, Lingyan Yu, Yuhua Zhao, Zhenwei Yu   +5 more
doaj   +1 more source

Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings [PDF]

Introduction: SARS-CoV-2 is now endemic and expected to remain a health threat, with new variants continuing to emerge and the potential for vaccines to become less effective.
Andrew, Melissa, Aubrey-Bassler, Kris, Barber, David, Barrett, Brendan, Butler, Christopher C, Condon, Amanda, Crampton, Noah, da Costa, Bruno R., Dahrouge, Simone, Daley, Peter, Damji, Ali, Fowler, Robert, Garies, Stephanie, Greiver, Michelle, Hosseini, Banafshe, Hudon, Catherine, Hulme, Jennifer, Isenor, Jennifer, Jüni, Peter, Lee, Todd C, McBrien, Kerry, McDonald, Emily G, Murthy, Srinivas, Selby, Peter   +23 more
core   +2 more sources

IPNA clinical practice recommendations on care of pediatric patients with pre-existing kidney disease during seasonal outbreak of COVID-19 [PDF]

The coronavirus disease 2019 (COVID-19) pandemic, instigated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has profoundly impacted healthcare infrastructures around the globe.
Admani B., Alhasan K. A., Allen U., Amer Y. S., Ashoor I. F., Bagga A., Bhimma R., Bonilla-Felix M., Boyer O., Bresolin N. L., Coccia P., Dharnidharka V., Duzova A., Esezobor C., Exantus J., Filler G., Haffner D., Hari P., Khan S. A., Koch V., Koh J., Ma A., Mantan M., Marlais M., McCulloch M., Montini G., Morello W., Prestidge C., Raina R., Restrepo J. M., Rodriguez L. I., Safouh H., Sethi S. K., Smith J. M., Temsah M. -H., Trnka P., Vasudevan A., Zhong X.   +37 more
core   +1 more source

Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.

PLoS ONE
Nirmatrelvir/Ritonavir, acting as an effective agent against COVID-19, has achieved considerable results in clinical studies in terms of drug efficacy. However, there is little research about its medication safety.
Ji Sun, Xuanyu Deng, Juanjuan Huang, Gefei He, Shiqiong Huang   +4 more
doaj   +1 more source

Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective

Drugs - Real World Outcomes
Background and objectives Nirmatrelvir/ritonavir was administered orally to manage mild to moderate symptoms of COVID-19 in adult patients. The objectives of this study were to (i) evaluate the cost-effectiveness of prescribing nirmatrelvir/ritonavir ...
Ee Vien Low, Hoon Shien Teh, Nicholas Yee Liang Hing, Suresh Kumar Chidambaram, Mohan Dass Pathmanathan, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +14 more
doaj   +1 more source

A Case Report of Severe Bradycardia Associated With Nirmatrelvir-ritonavir Drug-drug Interactions

Cardiology Discovery
. With the increasing use of nirmatrelvir-ritonavir in older COVID-19 patients, adverse drug reactions due to drug-drug interactions have become more frequent.
Zhiqing Fu, Yan Guo, Shuai Li, Yang Shi, Hanjia Gao   +4 more
doaj   +1 more source

Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy [PDF]

A 56-year-old woman who received CD19 chimeric antigen receptor-T cell therapy for refractory diffuse large B-cell lymphoma developed severe coronavirus disease 2019 (COVID-19) and was treated with nirmatrelvir/ritonavir in April 2022.
Fujii, Masanori, Fujii, Nobuharu, Higo, Hisao, Hotta, Katsuyuki, Ichihara, Eiki, Maeda, Yoshinobu, Makimoto, Go, Matsumoto, Chiaki, Miyahara, Nobuaki, Ninomiya, Kiichiro, Ohashi, Kadoaki, Rai, Kammei, Tabata, Masahiro, Yamashita, Masahiro   +13 more
core   +1 more source

Nirmatrelvir and ritonavir combination against COVID‐19 caused by omicron BA.2.2 in the elderly: A single‐center large observational study

Immunity, Inflammation and Disease
Background Since coronavirus 2019 (COVID‐19) swept the world, a variety of novel therapeutic and prevention strategies have been developed, among which nirmatrelvir–ritonavir is highly recommended.
Can Chen, Ranyi Li, Shuliang Xing, Lei Cao, Yue Qu, Qianzhou Lv, Xiaoyu Li, Zhangzhang Chen   +7 more
doaj   +1 more source

Case report: Paralytic ileus resulted from nirmatrelvir/ritonavir-tacrolimus drug-drug interaction in a systemic lupus erythematosus patient with COVID-19

Frontiers in Pharmacology
Patients with systemic autoimmune rheumatic diseases are at a high risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and effective antiviral treatments including nirmatrelvir/ritonavir can improve their outcomes.
Wei Zhang, Wei Zhang, Xingguo Zhang, Xingguo Zhang, Jinming Han, Wen Zhang, Jiarui Xu, Jiarui Xu, Xin Zhang, Hongjun Bian, Chong Meng, Deya Shang, Yi Zhou, Dawei Wang, Baobao Feng, Baobao Feng   +15 more
doaj   +1 more source

Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort study [PDF]

Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID-19, but the effect of treatment during acute infection on risk of Long COVID is unknown.
Beatty, Alexis L, Carton, Thomas W, Deeks, Steven G, Durstenfeld, Matthew S, Henrich, Timothy J, Hsue, Priscilla Y, Isasi, Carmen, Lin, Feng, Marcus, Gregory M, Olgin, Jeffrey E, Peluso, Michael J, Peyser, Noah D, Pletcher, Mark J   +12 more
core   +1 more source